Work

TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice

Year: 2024

Type: article

Abstract: after treatment, an observation also made in samples from patients treated with dual TGF-β neutralization and ICB. These findings provide the scientific rationale for the use of PD-L1 ICB and TGF-β neutralization in newly diagnosed patients with carcinomas prior to definitive treatment of locoregional disease.

Source: iScience

DOI: 10.1016/j.isci.2024.110520

Authors: Magdalena Fay, Cem Sievers, Yvette Robbins, Xinping Yang, Angel Huynh, Jason M. Redman, James W. Hodge, Jeffrey Schlom, James L. Gulley, Clint T. Allen, Marco Craveiro

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,150

Funders: National Institutes of Health, National Cancer Institute

Award: Enhancing anti-tumor immunity in head and neck neoplasms

OpenAlex ID: W4400646090

FWCI: 1.226

Cites: 40

Cited by: 8

Related to: 10